A randomized trial demonstrating successful boosting responses following simultaneous aerosols of measles and rubella (MR) vaccines in school age children.
The reactogenicity and immunogenicity of combined measles and rubella (MR) booster vaccination, via aerosol and subcutaneous routes, was assessed in 562 healthy children. Rates of rubella seroconversion and geometric mean titers (GMT) were similar for both routes. Rates of measles PN seroconversion, GMT and measles ELISA post-vaccination seropositivity and seroconversion rate were each higher for aerosol vaccine (54%, 3928 IU/l, 99.6 and 98.8%), than for subcutaneous vaccine (7%, 866 IU/l, 92.2 and 82.4%) (P<0.01). Reactogenicity was higher for subcutaneous vaccine (P<0.05). This study demonstrates that aerosol vaccine was more immunogenic for measles antibodies, and equally immunogenic for rubella antibodies. Aerosol vaccine was less reactogenic.
Sepúlveda-Amor
Jaime
J
National Institute of Public Health, Instituto Nacional de Salud Pública/Escuela de Salud Pública de México, Ave. Universidad 655, CP62508 Cuernavaca, Mor., Mexico.
Valdespino-Gómez
José Luis
JL
García-García
Maria de Lourdes
Mde L
Bennett
John
J
Islas-Romero
Rocío
R
Echaniz-Aviles
Gabriela
G
de Castro
Jorge Fernandez
JF
D000336:Aerosols; D000914:Antibodies, Viral / Q000097:blood; D000917:Antibody Formation; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D007117:Immunization, Secondary; D007279:Injections, Subcutaneous; D008457:Measles / Q000276:immunology*; D008458:Measles Vaccine / Q000008:administration & dosage* / Q000009:adverse effects / Q000276:immunology; D008459:Measles virus / Q000276:immunology; D012409:Rubella / Q000276:immunology / Q000517:prevention & control; D012411:Rubella Vaccine / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology*
D000336:Aerosols; D000914:Antibodies, Viral; D008458:Measles Vaccine; D012411:Rubella Vaccine